AA

Ala Alenazi

Investment Manager at Kinnevik

London, England

Overview 

Ala Alenazi is currently serving as the VC & Growth at Kinnevik in London, specializing in techbio investments with a background in molecular genetics. With a Ph.D. from the University of Cambridge and experience at notable organizations like Ascension and EIT Health, Ala has excelled in venture capital, life sciences, and healthcare consulting, demonstrating strong leadership and analytical skills in project management and market research.

Work Experience 

  • Investment Manager

    2024 - Current

    Investing in bio + ai Portfolio: Recursion (Nasdaq: RXRX), Enveda Biosciences

  • Board Observer

    2022 - 2023

  • Principal, Life Fund

    2022 - 2023

    Investments: Acurable, Tailor Bio, Kuano, NunaBio, Panakeia, Neuronostics and Aparito (2024, exit to Eli Lilly)

  • Associate, Life Fund

    2021 - 2022

    Investments: Novai, Stablepharma, MedAll, ExSeed, Qureight, Veratrak, AMLo Biosciences and NebuFlow Ascension Life Fund is an EIS fund that invests in UK-based Seed+/Series A techbio companies.

  • Expert Evaluator & Panel (Biotech)

    2022 - 2023

  • Board Observer

    2022 - 2023

  • Board Member

    2023 - 2023

  • Expert - Accelerate@Babraham

    2021 - 2023

  • Board Observer

    2022 - 2023

  • Healthcare Mentor

    2021 - 2023

  • Judge - Libra Programme 2.0

    2022 - 2023

Articles About Ala

Relevant Websites